Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹ Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as ...

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

Phase III program in food allergy (FA) planned for H2 2026 ...

CSU affects nearly 4 million people in Europe, with over 50% of patients remaining symptomatic despite H1-antihistamines2-4 ...

. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...

We are an innovative medicines company with research and development at our core. Our R&D engine powers an industry-leading pipeline focused on delivering transformative medicines to fight disease, ...

Novartis Pipeline Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...